MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - indian pharma
- CADILA HEALTHCARE - ASTRAZENECA PHARMA
CADILA HEALTHCARE vs ASTRAZENECA PHARMA - Comparison Results
CADILA HEALTHCARE Change
Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More
ASTRAZENECA PHARMA 
AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More
Current Valuations
| CADILA HEALTHCARE | ASTRAZENECA PHARMA | CADILA HEALTHCARE/ ASTRAZENECA PHARMA |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 29.4 | 116.0 | 25.4% | View Chart |
| P/BV | x | 3.5 | 33.9 | 10.4% | View Chart |
| Dividend Yield | % | 1.0 | 0.0 | - |
Financials
 CADILA HEALTHCARE  ASTRAZENECA PHARMA |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| CADILA HEALTHCARE Mar-19 |
ASTRAZENECA PHARMA Mar-18 |
CADILA HEALTHCARE/ ASTRAZENECA PHARMA |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 432 | 1,278 | 33.8% | |
| Low | Rs | 306 | 883 | 34.7% | |
| Sales per share (Unadj.) | Rs | 128.6 | 228.4 | 56.3% | |
| Earnings per share (Unadj.) | Rs | 18.5 | 10.4 | 179.0% | |
| Cash flow per share (Unadj.) | Rs | 24.4 | 16.3 | 150.0% | |
| Dividends per share (Unadj.) | Rs | 3.50 | 0 | - | |
| Dividend yield (eoy) | % | 0.9 | 0 | - | |
| Book value per share (Unadj.) | Rs | 101.5 | 98.8 | 102.7% | |
| Shares outstanding (eoy) | m | 1,023.74 | 25.00 | 4,095.0% | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 2.9 | 4.7 | 60.7% | |
| Avg P/E ratio | x | 19.9 | 104.2 | 19.1% | |
| P/CF ratio (eoy) | x | 15.1 | 66.4 | 22.8% | |
| Price / Book Value ratio | x | 3.6 | 10.9 | 33.3% | |
| Dividend payout | % | 18.9 | 0 | - | |
| Avg Mkt Cap | Rs m | 378,170 | 27,008 | 1,400.2% | |
| No. of employees | `000 | 12.4 | 1.4 | 917.3% | |
| Total wages/salary | Rs m | 21,241 | 1,535 | 1,383.5% | |
| Avg. sales/employee | Rs Th | 10,585.0 | 4,210.9 | 251.4% | |
| Avg. wages/employee | Rs Th | 1,707.8 | 1,132.2 | 150.8% | |
| Avg. net profit/employee | Rs Th | 1,526.5 | 191.1 | 798.9% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 131,656 | 5,710 | 2,305.7% | |
| Other income | Rs m | 2,011 | 123 | 1,641.6% | |
| Total revenues | Rs m | 133,667 | 5,833 | 2,291.8% | |
| Gross profit | Rs m | 29,731 | 463 | 6,422.8% | |
| Depreciation | Rs m | 5,986 | 147 | 4,061.1% | |
| Interest | Rs m | 1,935 | 0 | - | |
| Profit before tax | Rs m | 23,821 | 438 | 5,438.6% | |
| Minority Interest | Rs m | 469 | 0 | - | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
| Tax | Rs m | 5,303 | 179 | 2,964.2% | |
| Profit after tax | Rs m | 18,987 | 259 | 7,328.1% | |
| Gross profit margin | % | 22.6 | 8.1 | 278.6% | |
| Effective tax rate | % | 22.3 | 40.8 | 54.5% | |
| Net profit margin | % | 14.4 | 4.5 | 317.8% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 84,981 | 3,209 | 2,648.0% | |
| Current liabilities | Rs m | 73,425 | 2,070 | 3,548.0% | |
| Net working cap to sales | % | 8.8 | 20.0 | 44.0% | |
| Current ratio | x | 1.2 | 1.6 | 74.6% | |
| Inventory Days | Days | 75 | 72 | 103.0% | |
| Debtors Days | Days | 110 | 35 | 313.7% | |
| Net fixed assets | Rs m | 133,493 | 790 | 16,891.4% | |
| Share capital | Rs m | 1,024 | 50 | 2,048.0% | |
| "Free" reserves | Rs m | 102,839 | 2,419 | 4,250.8% | |
| Net worth | Rs m | 103,863 | 2,469 | 4,206.2% | |
| Long term debt | Rs m | 39,497 | 0 | - | |
| Total assets | Rs m | 234,831 | 4,605 | 5,099.0% | |
| Interest coverage | x | 13.3 | NM | - | |
| Debt to equity ratio | x | 0.4 | 0 | - | |
| Sales to assets ratio | x | 0.6 | 1.2 | 45.2% | |
| Return on assets | % | 8.9 | 5.6 | 158.4% | |
| Return on equity | % | 18.3 | 10.5 | 174.2% | |
| Return on capital | % | 18.3 | 17.7 | 103.1% | |
| Exports to sales | % | 0 | 0 | - | |
| Imports to sales | % | 0 | 0 | - | |
| Exports (fob) | Rs m | NA | NA | - | |
| Imports (cif) | Rs m | NA | NA | - | |
| Fx inflow | Rs m | 48,404 | 300 | 16,158.9% | |
| Fx outflow | Rs m | 11,593 | 2,015 | 575.4% | |
| Net fx | Rs m | 36,811 | -1,715 | -2,146.0% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 28,823 | 88 | 32,790.7% | |
| From Investments | Rs m | -57,387 | -94 | 61,310.9% | |
| From Financial Activity | Rs m | 18,846 | NA | - | |
| Net Cashflow | Rs m | -7,105 | -6 | 124,649.1% | |
Share Holding
| Indian Promoters | % | 74.8 | 0.0 | - | |
| Foreign collaborators | % | 0.0 | 75.0 | - | |
| Indian inst/Mut Fund | % | 8.3 | 0.3 | 2,766.7% | |
| FIIs | % | 5.9 | 15.7 | 37.6% | |
| ADR/GDR | % | 0.0 | 0.0 | - | |
| Free float | % | 11.0 | 9.1 | 120.9% | |
| Shareholders | 44,069 | 12,856 | 342.8% | ||
| Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare CADILA HEALTHCARE With: STERLING BIOTECH SANOFI INDIA ALEMBIC PHARMA PROCTER & GAMBLE HEALTH NOVARTIS
Compare CADILA HEALTHCARE With: MYLAN (US) ADCOCK INGRAM (S. Africa) ACTAVIS (US) TEVA PHARMA (Israel)
Today's Market
Sensex Slips Over 550 Points; Nifty Falls Below 10,700 Mark(11:30 am)
Share markets in India have extended early losses and are presently trading deep in the red.Benchmark indices edged lower today tracking weak Asian markets.
Related Views on News
ASTRAZENECA PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 2.5% (Quarterly Result Update)
May 20, 2020 | Updated on May 20, 2020For the quarter ended March 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 96 m (down 2.5% YoY). Sales on the other hand came in at Rs 2 bn (up 2.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
CADILA HEALTHCARE Announces Quarterly Results (2QFY20); Net Profit Down 79.3% (Quarterly Result Update)
Nov 15, 2019 | Updated on Nov 15, 2019For the quarter ended September 2019, CADILA HEALTHCARE has posted a net profit of Rs 829 m (down 79.3% YoY). Sales on the other hand came in at Rs 34 bn (up 13.7% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.
CADILA HEALTHCARE Announces Quarterly Results (1QFY20); Net Profit Down 28.9% (Quarterly Result Update)
Aug 13, 2019 | Updated on Aug 13, 2019For the quarter ended June 2019, CADILA HEALTHCARE has posted a net profit of Rs 3 bn (down 28.9% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.
ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)
Aug 8, 2019 | Updated on Aug 8, 2019For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
CADILA HEALTHCARE Announces Quarterly Results (4QFY19); Net Profit Down 21.0% (Quarterly Result Update)
May 30, 2019 | Updated on May 30, 2019For the quarter ended March 2019, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (down 21.0% YoY). Sales on the other hand came in at Rs 37 bn (up 14.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.
More Views on NewsMost Popular
How to Find the Best Stocks for Day Trading - 1(Fast Profits Daily)
Jul 2, 2020In the first of two videos, I'll show you how to identify the best stocks for intraday trading.
Two Agri Stocks Are Likely to Outperform Even in this Market(Profit Hunter)
Jul 2, 2020Why we have recommended two agriculture stocks for our Hidden Treasure subscribers. Read on...
These 3 Recent Events Will Impact the Price of Gold(Fast Profits Daily)
Jul 1, 2020Recent developments in the bullion market may put some short term pressure on gold prices.
Smallcaps Are in a Sweet Spot Again: Are You Buying?(Profit Hunter)
Jul 3, 2020This is why I believe smallcaps are the place to be in the near future.
MoreOUR TOP 5 IDEAS
- Free Report: Multibagger Stock Ideas 2020
- Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
- A Guide to some of the Most Lucrative Stocks in the Market. Download For Free!
- Free Report: The Secret to Increasing Your Trading Profits Daily!
- No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.
CADILA HEALTHCARE SHARE PRICE
Jul 14, 2020 12:07 PM
TRACK CADILA HEALTHCARE
- Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON CADILA HEALTHCARE
CADILA HEALTHCARE 8-QTR ANALYSIS
COMPARE CADILA HEALTHCARE WITH
FEATURED VIDEOS
![]( "What No One Told You About Finding the Best Penny Stocks")
What No One Told You About Finding the Best Penny Stocks![]( "Using Price Action to Identify Trading Opportunity in Defense Stocks")
Using Price Action to Identify Trading Opportunity in Defense Stocks![]( "Three Charts on One of the Quickest Bull Markets in History")
Three Charts on One of the Quickest Bull Markets in History![]( "This is Where You Will Find the Most Promising Bets for Post Covid Rebound")
This is Where You Will Find the Most Promising Bets for Post Covid Rebound![]( "Here")
Here's How You Can Make Big Money from Penny Stocks
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.